An investigator-initiated Phase 1/2 trial is ongoing at St. Jude Children’s Research Hospital investigating Auxora as a potential therapy for acute pancreatitis as a result of asparaginase treatment for pediatric patients with ALL. Patients enrolled in this trial are treated with a daily dose of Auxora for four days with the primary endpoints of safety, tolerability and the reduction in development of complications of acute pancreatitis including necrotizing pancreatitis and SIRS.

For more details on the clinical trial, please visit: Study of Auxora to Reduce the Severity of Pancreatitis Due to Asparaginase